The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Janssen-Cilag Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
261 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 80 mg film-coated tablets blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 240 mg film-coated tablets bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 240 mg film-coated tablets blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAZCLUZE lazertinib 80 mg film-coated tablets bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DARZALEX daratumumab 100 mg/5 mL concentrated solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DARZALEX daratumumab 400 mg/20 mL concentrated solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Cellular Therapies - T cells-Ciltacabtagene autoleucel, cryopreserved-T-CARVYKTI - Janssen-Cilag Pty Ltd - Injection, intravenous infusion - Bag.
-
Cancellation by sponsorRequested by Janssen-Cilag Pty Ltd
-
Jan-2025Prescription medicine evaluationActive ingredient: daratumumab.
-
Jan-2025Prescription medicine evaluationActive ingredient: guselkumab.